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Topical ﬂ uorouracil after surgery for ocular surface 
squamous neoplasia in Kenya: a randomised, double-blind, 
placebo-controlled trial
Stephen Gichuhi, Ephantus Macharia, Joy Kabiru, Alain M’bongo Zindamoyen, Hilary Rono, Ernest Ollando, Joseph Wachira, Rhoda Munene, 
John Maina, Timothy Onyuma, Mandeep S Sagoo, Helen A Weiss, Matthew J Burton
Summary
Background Ocular surface squamous neoplasia (OSSN) is an aggressive eye tumour particularly aﬀ ecting people 
with HIV in Africa. Primary treatment is surgical excision; however, tumour recurrence is common. We assessed the 
eﬀ ect of ﬂ uorouracil 1% eye drops after surgery on recurrence.
Methods We did this multicentre, randomised, placebo-controlled trial in four centres in Kenya. We enrolled patients 
with histologically proven OSSN aged at least 18 years. After standard surgical excision, participants were randomly 
allocated to receive either topical ﬂ uorouracil 1% or placebo four times a day for 4 weeks. Randomisation was stratiﬁ ed 
by surgeon, and participants and trial personnel were masked to assignment. Patients were followed up at 1 month, 
3 months, 6 months, and 12 months. The primary outcome was clinical recurrence (supported by histological 
assessment where available) by 1 year, and analysed by intention to treat. The sample size was recalculated because 
events were more common than anticipated, and trial enrolment was stopped early. The trial was registered with 
Pan-African Clinical Trials Registry (PACTR201207000396219).
Findings Between August, 2012, and July, 2014, we assigned 49 participants to ﬂ uorouracil and 49 to placebo. 
Four participants were lost to follow-up. Recurrences occurred in ﬁ ve (11%) of 47 patients in the ﬂ uorouracil group 
and 17 (36%) of 47 in the placebo group (odds ratio 0·21, 95% CI 0·07–0·63; p=0·01). Adjusting for passive smoking 
and antiretroviral therapy had little eﬀ ect (odds ratio 0·23; 95% CI 0·07–0·75; p=0·02). Adverse eﬀ ects occurred 
more commonly in the ﬂ uorouracil group, although they were transient and mild. Ocular discomfort occurred in 
43 of 49 patients in the ﬂ uorouracil group versus 36 of 49 in the placebo group, epiphora occurred in 24 versus ﬁ ve, 
and eyelid skin inﬂ ammation occurred in seven versus none.
Interpretation Topical ﬂ uorouracil after surgery substantially reduced recurrence of OSSN, was well-tolerated, and its 
use recommended.
Funding British Council for Prevention of Blindness and the Wellcome Trust.
Copyright © Gichuhi et al. Open Access article distributed under the terms of CC BY.
Introduction
Ocular surface squamous neoplasia (OSSN) covers a range 
of conjunctival and corneal diseases, from intra-epithelial 
dysplasia to invasive squamous cell carcinoma.1 Risk 
factors for OSSN include ultraviolet radiation, HIV 
infection, and human papillomavirus infection.2 In 
temperate regions, OSSN is uncommon, usually growing 
slowly, and most often aﬀ ects elderly men. By contrast, in 
sub-Saharan Africa, OSSN is more common and 
aggressive.3 It aﬀ ects younger adults, predominately 
women (around two-thirds of cases), and is strongly 
associated with HIV infection (in about 70% of cases). 
OSSN has a wide range of clinical phenotypes and late 
presentation with invasive orbital disease is not uncommon 
(ﬁ gure 1). Surgical excision is the mainstay of treatment, 
although primary chemotherapy has also been used 
(appendix). OSSN often recurs after surgery. The highest 
recorded recurrence is 67%.4 Recurrence is a particular 
problem in sub-Saharan Africa, where it typically occurs in 
30–40% of patients.4–7 In temperate climates, recurrence 
typically occurs in 5–25% of patients (appendix). Surgical 
outcomes seem to be aﬀ ected by delays in diagnosis, 
tumour size, histological grade, ocular location, scleral 
invasion, excision margin involvement, prior excision, and 
coexisting xeroderma pigmentosum.5,8,9 Several adjunctive 
treatment regimens are used during or after surgery to 
reduce recurrence: cryotherapy, topical chemotherapy 
(mitomycin and ﬂ uorouracil), interferon alfa-2b, retinoic 
acid, and radiotherapy (appendix p 1, 3, 7, 11, 13, 14). Most 
data on adjuvant treatment are case series. There is one 
previous randomised trial, from Australia, which assessed 
the eﬀ ectiveness of topical mitomycin and there are no 
trial data on interventions for people with HIV.10,11 Radical 
surgery (enucleation or exenteration) is usually needed for 
advanced disease.12
The antimetabolite ﬂ uorouracil is often used in 
ophthalmology, particularly for its anti-scarring properties 
during surgical procedures (trabeculectomy, pterygium 
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excision, and lacrimal surgery).13 Eye drops containing 1% 
ﬂ uorouracil have also been used for several years to treat 
patients with OSSN after tumour excision (appendix 
p 11), on the basis of case series, which suggest that 
ﬂ uorouracil reduces tumour recurrence and is safe.14–20 
However, there are no data from trials. Fluorouracil is 
widely available and relatively cheap in sub-Saharan 
Africa, therefore, if shown to be an eﬀ ective adjuvant, it 
would be a deliverable intervention.
We assessed whether use of ﬂ uorouracil 1% eye drops 
could reduce recurrence of OSSN following surgical 
excision in Kenya.
Methods
Study design and participants
We did a double-blind, parallel-group, randomised, 
placebo-controlled trial at four centres in Kenya: Kenyatta 
National Hospital Eye Clinic in Nairobi, PCEA Kikuyu 
Eye Unit in central Kenya, Sabatia Eye Hospital in 
western Kenya, and Kitale District Hospital in the north 
Rift Valley.
We enrolled consecutive patients presenting with 
suspicious conjunctival lesions. Entry criteria were: 
histologically proven OSSN involving two or fewer 
quadrants; attendance for follow-up within the ﬁ rst 
2 months after excision; healing of the excision site; and 
age at least 18 years. Exclusion criteria were: previous 
treatment with topical antimetabolite drugs such as 
ﬂ uorouracil or mitomycin to the same eye or systemic 
cytotoxic drugs; extensive disease requiring more radical 
surgery than a simple excision; and pregnant or 
breastfeeding mothers. Patients were not enrolled if they 
did not think that they could return for follow-up.
All participants gave written informed consent before 
enrolment. Ethics approval was granted by the Kenyatta 
National Hospital/University of Nairobi ethics and 
research committee and the London School of Hygiene 
& Tropical Medicine ethics committee. Approval was also 
obtained from the Kenya Pharmacy and Poisons Board to 
produce and use the active intervention drops because 
they are not commercially available.
An independent data and safety monitoring board 
oversaw the study, conﬁ rmed data integrity, and approved 
the results and report for release. Trial personnel received 
good clinical practice training and certiﬁ cation. This 
study adhered to the tenets of the Declaration of Helsinki.
Randomisation and masking
Participants were randomly assigned (1:1) to either 
ﬂ uorouracil 1% or placebo eye drops. The ﬂ uorouracil 
eye drops were prepared by dilution of ﬂ uorouracil 
Research in context
Evidence before this study
Ocular surface squamous neoplasia (OSSN) is an eye cancer, 
common in people with HIV. A Cochrane systematic review 
from 2013 showed no evidence from trials for the eﬀ ectiveness 
of interventions used in this population. We searched electronic 
databases (PubMed, Embase, The Cochrane Library), clinical trial 
registries (WHO International Clinical Trials Registry Platform 
and the US National Institutes of Health ClinicalTrials.gov), and 
international conference proceedings of HIV/AIDS and 
AIDS-related cancers from the AIDS Education Global Education 
System for studies published up to Aug 31, 2015, irrespective of 
language or publication status. We used the terms “randomized 
controlled trial”, “controlled clinical trial”, “randomized”, 
“placebo”, “drug therapy”, “randomly”, “trial”, “conjunctiva*”, 
“ocular surface”, “carcinoma”, “cancer”, “neoplasia”, “neoplasm”, 
“neoplastic”, “dysplasia”, “dysplastic”, “squamous”, and 
“squamous cell”. We found only one trial, on topical mitomycin 
in a non-HIV-infected population in Australia. We identiﬁ ed 
some case series and case reports (appendix). Only series that 
reported recurrence as an outcome were included.
Added value of this study
Our study provides the ﬁ rst evidence from a trial of the 
eﬀ ectiveness of ﬂ uorouracil as adjunctive treatment for 
OSSN. Our results show that the simple and relatively 
inexpensive use of 4 weeks of ﬂ uorouracil 1% eye drops after 
surgical excision substantially reduced the relative risk of 
recurrence compared with placebo and was safe. There were 
transient side-eﬀ ects, such as watery eye, discomfort when 
taking the drops, and eyelid skin inﬂ ammation but these were 
mostly mild and resolved in a few weeks after completion of 
4 week treatment.
Implications of all the available evidence
Recurrence is a huge issue in the management of this common 
and aggressive eye disease. Fluorouracil does not need stringent 
storage conditions and cytotoxics have a low risk of 
contamination. It is on the WHO Essential Medicines List, and is 
a widely available and low-cost option, particularly in 
sub-Saharan Africa, which has the highest incidence of OSSN in 
the world. Translation of these trial results into clinical practice 
is therefore feasible. 
Figure 1: Ocular surface squamous neoplasia
Moderately diﬀ erentiated conjunctival squamous cell carcinoma, (A) moderate size, (B) large lesion involving the 
cornea, limbus, and extending to the fornix. Fornix involvement is often associated with orbital spread.
A B
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50 g/L solution for injection in hydroxypropyl 
methylcellulose 0·7% artiﬁ cial tear eye drops. The 
placebo was the same hydroxypropyl methylcellulose 
0·7% artiﬁ cial tear eye drops.
The randomisation sequence was generated by 
computer by the trial statistician using Stata (version 12). 
The permuted block size (known only to the statistician) 
varied randomly between two and four, and 
randomisation was stratiﬁ ed by surgeon. The allocation 
sequence was transferred to the manufacturing 
pharmacy, where an independent pharmacist applied 
labels with sequential code numbers to the appropriate 
eye drop bottles. Participants, clinicians, and study 
personnel were masked to the allocation: the bottles, 
liquid content, and packaging had identical appearances. 
The supervising clinician at each of the four study centres 
issued the trial drug to participants. The allocation 
followed the order of enrolment.
Procedures
Lesions involving two or fewer quadrants of the 
conjunctiva were fully excised with a 4 mm clear margin 
by the no-touch technique, with use of an operating 
microscope and under local anaesthesia.21 Absolute 
alcohol was applied to any corneal component of the 
tumour to loosen it and facilitate dissection. The 
conjunctival component was dissected down to bare 
sclera. Cryotherapy was not applied, because it is not 
generally available in sub-Saharan Africa. Topical 
adrenaline, and where necessary mild diathermy, were 
used for haemostasis. The conjunctiva around the defect 
was undermined and mobilised for primary closure. 
Specimens were placed on suture-pack polystyrene, to 
keep the tissue ﬂ at and oriented for the pathologist, and 
ﬁ xed in 10% neutral buﬀ ered formalin. All 
histopathological tests were done centrally and reported 
by a single pathologist. Combined gentamicin 0·3% and 
prednisolone acetate 1% eye drops were applied four 
times per day for 3–4 weeks after surgery. Patients were 
reviewed after about 4 weeks to conﬁ rm wound healing 
and for recruitment into the trial.
Participants were asked to self-administer one drop of 
their allocated medication four times a day to the aﬀ ected 
eye for 4 weeks. Each participant was given a 28 day 
medication diary to monitor treatment. They were asked 
to record each dose taken or missed. The record card had 
a similar diary for adverse eﬀ ects (pain or burning 
sensation, excessive tears, and redness).
Participants underwent a detailed ophthalmic 
examination with a slit-lamp biomicroscope before 
surgery and at about 1 month after surgery. After 
enrolment, follow-up visits were scheduled for 1 month, 
3 months, 6 months, and 12 months after randomisation. 
Participants were telephoned 1 week before their 
appointments to remind them. Individuals who missed 
follow-up visits were contacted by telephone. At each 
follow-up visit, a symptom history was taken and a 
detailed ophthalmic examination was done for evidence 
of recurrent disease. On each examination, high-
resolution digital images of the surface of the eyes were 
taken. In addition, we assessed whether the lacrimal 
drainage system was blocked using the dye disappearance 
test. Fluorescein dye was applied in both eyes in the 
inferior conjunctival fornix and the tear ﬁ lm observed 
with the cobalt blue light of the slit lamp after 5 min for 
clearance of the dye. The presence of dye after this time 
was considered positive, indicating a functional or 
anatomical blockage.
HIV status was initially tested by ELISA using 
Vironostika antigen/antibody kit (Biomerieux, France) 
then later changed to rapid tests with Alere Determine 
HIV-1/2 Ag/Ab (Alere, USA) and Unigold (Trinity Biotech, 
USA). CD4 count was measured with FacsCount (Becton 
Dickinson, USA). Serum retinol concentration was 
quantiﬁ ed by high-performance liquid chromatography 
(SHIMADZU Prominence HCT2010, Japan).
When an obvious regrowth was found, re-excision for 
treatment and histopathology was advised. If a small 
potentially suspicious change was observed, it was 
initially photographed, the size measured, and the 
participant examined more frequently than the scheduled 
study visits. If on subsequent visits the lesion had 
progressed, the lesion was re-excised and sent for 
histopathology; the date of recurrence was recorded as 
the ﬁ rst time the possible regrowing lesion was noticed.
Outcomes
The primary outcome was clinical recurrence of the 
lesion at any time during the ﬁ rst year of follow-up, 
conﬁ rmed by histological assessment where available. 
The secondary outcomes were time to recurrence, 
cofactors of recurrence, and adverse events.
Primary outcome events were assessed and conﬁ rmed 
centrally by an ophthalmologist, who had either directly 
examined all patients at Kenyatta National Hospital and 
Kikuyu Eye Unit, or reviewed the clinical images from 
Sabatia Eye Hospital and Kitale District Hospital, 
supported by histopathological results. For cases where 
histopathology was not available, mostly because the 
participant did not return for the repeat surgery, the 
images of recurrent lesions were reviewed by two 
consultant ophthalmologists experienced in OSSN in 
east Africa to conﬁ rm clinical recurrence. Adverse eﬀ ects 
were monitored by reviewing the medication diary with 
the participant and asking about discomfort and tearing.
Statistical analysis
Case series of the use of surgical excision with or without 
adjuvant ﬂ uorouracil treatment have reported 
recurrences in 3·2–43% of patients.7,19,22,23 Assuming a 
recurrence of 20% in the control group and 10% in the 
treatment group, power of 80%, and a two-sided α of 5%, 
the target sample size was initially calculated to be 
219 participants in each group. 1 year into the study, we 
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noted that recruitment was slow but recurrences were 
more common overall than anticipated, so after review 
by the trial steering committee in discussion with the 
data safety and monitoring board, a pragmatic decision 
was made to revise the sample size assuming that 30% of 
patients in the placebo group and 5% in the treatment 
group would have disease recurrence. As such, a sample 
size of 43 participants in each group would provide 80% 
power to detect an absolute diﬀ erence in recurrence rates 
of 25%.
The analysis was predeﬁ ned. We compared the two 
groups for balance in terms of predeﬁ ned factors that 
could have a bearing on aetiology or recurrence: age, sex, 
smoking history, outdoor occupation, HIV status, CD4 
count, vitamin A concentration, tumour size, prior 
excision, and histological grade.3,5,8,9 The primary analysis 
of the primary outcome and the safety analysis were 
done by intention to treat. Data were managed in 
Microsoft Access, cleaned, and transferred into Stata 
(version 12.1) for analysis.
We calculated the numbers of events, person-months, 
and rate of recurrence in each group. We estimated the 
eﬀ ect size as the odds ratio (OR) for recurrence, estimated 
by logistic regression, with 95% CIs. We adjusted the 
crude OR for the seven surgeons as a random eﬀ ect and 
for additional baseline factors that were greater in one 
group than the other.24 We analysed the eﬀ ect of the 
intervention on time to recurrence with Kaplan-Meier 
survival curves, and we used Cox regression to estimate 
hazard ratios and 95% CIs, adjusting for substantial 
baseline imbalances. To assess whether survival was the 
same by treatment group, we used the log rank test. We 
report the risk of any adverse eﬀ ects at any follow-up in 
the treated eye by group.
The trial is registered with the Pan-African Clinical 
Trials Registry, number PACTR201207000396219.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
Between August, 2012, and July 2014, 496 patients with 
conjunctival lesions had surgical excision followed by 
histopathological tests. 187 of these patients had OSSN 
and 309 had other pathological disease types. For all 
participants with OSSN, only one eye was involved. 
89 (48%) of 187 patients were ineligible. Therefore, we 
enrolled 98 patients (ﬁ gure 2). 49 patients were assigned 
to receive ﬂ uorouracil eye drops and 49 were assigned to 
placebo. 58 of 98 patients were enrolled at Kikuyu Eye 
Unit, 20 at Sabatia Eye Hospital, 12 at Kitale District 
Hospital, and eight at Kenyatta National Hospital. The 
ﬁ nal follow-up visits were scheduled for 12 months, 
although we included data from up to 13 months for late 
participants. Follow-up was completed in July, 2015. 
Four individuals without a recorded recurrence (two from 
each group) did not complete a full year of follow-up.
The main reasons for exclusion were: inability to return 
for regular follow-up (n=41), extensive disease requiring 
radical surgery (n=24), not returning at all after surgery 
(n=16), or returning more than 2 months after surgery 
(n=3; ﬁ gure 2). There were no signiﬁ cant diﬀ erences 
between the enrolled and non-enrolled patients in terms 
of age, sex, smoking, HIV infection, or stage of OSSN 
(excluding larger tumours; data not shown).
The mean age of all participants was 41·0 years 
(SD 11·3) and most were female. Baseline characteristics 
were reasonably balanced between the two groups with 
the exception of past passive cigarette smoking and use 
of antiretroviral therapy, which were more common in 
the placebo group than in the ﬂ uorouracil group, and 
therefore were adjusted for in the primary analysis 
(table 1).
By the end of follow-up, recurrent lesions had 
developed in 22 eyes of 22 participants. The 
four participants who did not complete a full year of 
follow-up were excluded from the primary analysis of 
clinical recurrence of the lesion by 1 year. Lesion 
recurrence was signiﬁ cantly less common in the 
 Figure 2: Trial proﬁ le
OSSN=ocular surface squamous neoplasia.
496 patients assessed for eligibility
187 OSSN conﬁrmed
98 randomly assigned
49 allocated to and received ﬂuorouracil 49 allocated to and received placebo
47 included in the analysis 47 included in the analysis
2 lost to follow-up 2 lost to follow-up
309 did not have OSSN
89 excluded
 41 anticipated diﬃculty with follow-up
 24 had extensive disease >two quadrants
 16 did not return after surgery
 3 returned more than 2 months after surgery
 1 prior use of mitomycin eye drops
 1 pregnant
 1 breastfeeding
 1 declined consent
 1 sphenoid wing meningioma (referred)
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ﬂ uorouracil group (ﬁ ve [11%] of 47 patients) than in the 
placebo group (17 [36%] of 47 patients; crude OR 0·21, 
95% CI 0·07–0·63; p=0·01). This eﬀ ect remained 
signiﬁ cant when adjusted for use of antiretroviral 
therapy and passive cigarette smoking (OR 0·23, 95% CI 
0·07–0·75; p=0·02). The relative risk of recurrence was 
reduced by 70·7% and the absolute diﬀ erence was 
25·6%. Treatment with ﬂ uorouracil after surgery for 
four patients would therefore prevent an estimated one 
recurrence (number needed to treat 3·9, 95% CI 
2·4–11·8).
16 of 22 recurrent lesions underwent repeated surgical 
excision and recurrent OSSN was conﬁ rmed by 
histopathology in all cases. Re-excision was not done for 
six recurrent cases: four participants in the placebo group 
did not return for repeat surgery or further follow-up 
after the recurrence was noted, and two participants in 
the placebo group died before re-excision could be done 
(one from a presumed myocardial infarction and one 
from HIV-related complications). The images of these 
cases were reviewed by two ophthalmologists experienced 
in OSSN in east Africa. All were judged to be recurrent 
OSSN disease on clinical grounds, in the context of 
previous histologically conﬁ rmed OSSN.
There was a signiﬁ cant diﬀ erence in the recurrence 
rate between the two groups over the follow-up period 
(hazard ratio [HR] 0·24, 95% CI 0·09–0·66; p=0·01; 
ﬁ gure 3), which changed slightly after adjusting for 
smoking and use of antiretroviral therapy (HR 0·32, 
95% CI 0·11–0·95; p=0·04). The test for proportional 
hazards assumption showed that the assumption of 
proportionality was appropriate (p=0·59). Median 
tumour-free survival was 7·3 months (IQR 2·3–13·5) in 
the ﬂ uorouracil group and 4·8 months (3·0–7·6) in the 
placebo group but the diﬀ erence was not statistically 
signiﬁ cant (p=0·23).
Sensitivity analysis, assuming the four participants 
who did not complete 1 year of follow-up did not have a 
Fluorouracil 
group (n=49)
Placebo group 
(n=49)
Sex
Male 17 (35%) 14 (29%)
Female 32 (65%) 35 (71%)
Age (years) 39·1 (9·2) 42·9 (13·0)
Marital status*
Single 6 (12%) 11 (22%)
Married 32 (65%) 28 (58%)
Divorced or separated 4 (8%) 2 (4%)
Widowed 7 (14%) 7 (14%)
Formal education (years)*
Tertiary (>12) 5 (10%) 4 (8%)
Secondary completed (12) 18 (37%) 20 (41%)
Some secondary (8–12) 4 (8%) 6 (12%)
Primary completed (8) 13 (27%) 11 (22%)
Some primary (<8) 6 (12%) 4 (8%)
None 3 (6%) 3 (6%)
Past cigarette smoking*
No 41 (84%) 32 (67%)
Yes 5 (10%) 4 (8%)
Passive (spouse or partner smokes) 3 (6%) 12 (25%)
Current cigarette smoking†
No 44 (90%) 41 (87%)
Yes 3 (6%) 0 (0%)
Passive (spouse or partner smokes) 2 (4%) 6 (13%)
Cigarettes smoked daily 9 (6) 13 (13)
Years of cigarette smoking 10·7 (6·8) 16·2 (7·4)
Location of current occupation*
Indoors 20 (41%) 19 (40%)
Outdoors 29 (59%) 29 (60%)
Wears hat or cap outdoors† 8 (16%) 6 (13%)
Wears sunglasses outdoors† 4 (8%) 4 (9%)
HIV infection‡ 29 (63%) 31 (71%)
Use of antiretroviral therapy§ 10 (22%) 19 (42%)
CD4 count (cells per μL)¶ 444 (370) 460 (421)
Serum retinol concentration (μg/L)|| 489 (157) 529 (215)
Vitamin A deﬁ ciency (serum retinol 
<300 μg/L)||
3 (6%) 3 (6%)
Tumour diameter (mm) 5·9 (2·6) 6·3 (2·4)
Prior excision 8 (16%) 9 (19%)
Histological grading of tumours
CIN 1 4 (8%) 4 (8%)
CIN 2 13 (27%) 8 (16%)
CIN 3 11 (22%) 14 (29%)
Carcinoma in situ 0 (0%) 1 (2%)
Poorly diﬀ erentiated squamous cell 
carcinoma
1 (2%) 1 (2%)
Moderately diﬀ erentiated 
squamous cell carcinoma
17 (35%) 18 (37%)
Well diﬀ erentiated squamous cell 
carcinoma
3 (6%) 3 (6%)
Surgical margin involvement 21 (43%) 19 (39%)
(Table 1 continues in next column)
Fluorouracil 
group (n=49)
Placebo group 
(n=49)
(Continued from previous column)
Stage of OSSN**
T1N0M0 15 (31%) 9 (18%)
T2N0M0 10 (20%) 9 (18%)
T3N0M0 23 (47%) 31 (63%)
T3N1M0 1 (2%) 0 (0%)
Data are n (%) or mean (SD). *Data missing for one participant in the placebo 
group. †Data missing for two participants in the placebo group. ‡Data missing for 
three participants in the ﬂ uorouracil group and ﬁ ve in the placebo group. 
§Data missing for three participants in the ﬂ uorouracil group and four in the 
placebo group. ¶Data missing for eight participants in the ﬂ uorouracil group and 
11 in the placebo group. ||Data missing for ten participants in the ﬂ uorouracil 
group and 13 in the placebo group. **As per the American Joint Committee on 
Cancer. CIN=cervical intra-epithelial neoplasia. OSSN=ocular surface squamous 
neoplasia. 
Table 1: Baseline characteristics 
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recurrence in the ﬁ rst year, made little diﬀ erence to the 
results (crude OR 0·21, 95% CI 0·07–0·64, p=0·01; 
adjusted OR 0·25, 95% CI 0·08–0·79, p=0·02; HR 0·25, 
95% CI 0·07–0·67, p=0·01; adjusted HR 0·33, 95% CI 
0·11–0·97, p=0·04) and the number needed to treat 
remained at four (4·1, 95% CI 2·5–12·5).
Tumour size at baseline was a signiﬁ cant cofactor of 
recurrence (crude OR 1·27, 95% CI 1·04–1·54, p=0·02). 
Participants who had a recurrence had signiﬁ cantly 
larger mean tumour diameter (7·3 mm, SE 0·26) than 
did patients who did not have a recurrence (5·8 mm, 
SE 0·66; p=0·01). There was no eﬀ ect modiﬁ cation by 
tumour size or rate of tumour growth before surgery, 
deﬁ ned as tumour diameter divided by duration between 
noticing the growth and time of surgery, assuming a 
linear rate (likelihood ratio test p=0·49). The mean 
growth rate was 1·6 mm per month (SE 0·61) in patients 
who had a recurrence and 1·7 mm per month (SE 0·22) 
in patients who did not. Surgical margin involvement 
was not a signiﬁ cant cofactor for recurrence (crude 
OR 1·28, 95% CI 0·49–3·33, p=0·62) and nor was having 
invasive carcinoma rather than carcinoma in situ at 
baseline (crude OR 1·09, 95% CI 0·42–2·81, p=0·87).
Adverse eﬀ ects were more common in the ﬂ uorouracil 
group than in the placebo group, as shown by analysis of 
the time to ﬁ rst adverse event (p=0·005; table 2). Epiphora 
(watery eye) was more common in the ﬂ uorouracil group 
than in the placebo group and the dye disappearance test 
became transiently positive in six patients in the 
ﬂ uorouracil group at 1 month. None of the participants 
with epiphora had a positive dye disappearance test at 
1 year. Ocular discomfort was more common in the 
ﬂ uorouracil group than in the placebo group at 1 month 
(p=0·004). In one (2%) patient, discomfort was suﬃ  cient 
to discontinue treatment after 3 weeks. After the 1 month 
visit, no participants reported ocular discomfort.
Seven participants, all in the ﬂ uorouracil group, 
developed inﬂ ammation or irritation of the eyelid skin 
after about 2–3 weeks of treatment. This was attributed 
to overﬂ ow spillage of the eye drop onto the skin. All skin 
changes fully resolved within 1 month. We advised all 
further enrollees to apply drops while holding a piece of 
tissue paper against the lid; subsequently, no episodes of 
eyelid skin irritation occurred.
Discussion
We showed that 4 weeks of treatment with topical 
ﬂ uorouracil 1% after surgical excision substantially 
reduced the 1 year recurrence of OSSN tumours. The 
study was done in a region with a relatively high 
incidence of OSSN, which is often associated with HIV 
infection, and where patients often present late with 
advanced disease. Tumour recurrence has been a major 
problem in managing this disease. Most of our 
participants were relatively young, and women 
outnumbered men, the typical demographic pattern in 
Africa.3 The whole range of OSSN disease was 
represented, enabling us to draw a general conclusion 
about the eﬀ ectiveness of the intervention.
This study was the ﬁ rst randomised controlled trial of 
topical ﬂ uorouracil as adjunctive treatment for OSSN. 
Figure 3: Kaplan-Meier analysis of time to recurrence
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Epiphora ·· ·· ··
1 month 24 (49%) 5 (10%) <0·001
3 months* 3 (6%) 2 (4%) 0·66
6 months† 1 (2%) 0 (0%) 0·32
12 months† 4 (8%) 0 (0%) 0·04
Positive dye disappearance test ·· ·· ··
At baseline 0 (0%) 1 (2%) 0·32
1 month 6 (12%) 1 (2%) 0·05
3 months* 1 (2%) 0 (0%) 0·32
6 months† 0 (0%) 0 (0%) -
12 months† 0 (0%) 0 (0%) -
Discomfort in the treated eye 
at 1 month‡
·· ·· 0·004
Occasional discomfort 21 (43%) 30 (61%) ··
Discomfort for <5 min 12 (24%) 3 (6%) ··
Discomfort for ≥5 min 4 (8%) 2 (4%) ··
Discomfort making 
treatment diﬃ  cult
6 (12%) 1 (2%) ··
Eyelid inﬂ ammation at 1 month 7 (14%) 0 (0%) <0·001
Any adverse event ·· ·· 0·005§
1 month 34 (69%) 19 (39%) ··
3 months 10 (20%) 9 (18%) ··
6 months 5 (10%) 1 (2%) ··
12 months 7 (14%) 6 (12%) ··
*48 patients in the ﬂ uorouracil group and 47 in the placebo group because of loss 
to follow-up. †47 participants in each group because of loss to follow-up. 
‡No participant reported any discomfort at 3 months, 6 months, or 12 months. 
§Computed with the stratiﬁ ed log-rank test for equality of survivor functions.
Table 2: Adverse events 
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However, our results are consistent with those of non-
randomised case series of adjuvant ﬂ uorouracil, which 
have reported similarly low proportions of recurrence.14–20 
Some investigators have reported the eﬀ ectiveness of 
ﬂ uorouracil as primary treatment in presumed OSSN 
lesions without surgical excision and histopathological 
assessment.14 We chose to test ﬂ uorouracil in this setting 
because it is cheap and readily available with a history of 
use and wide acceptance for other types of ophthalmic 
surgery. Fluorouracil is on WHO’s list of essential drugs. 
It does not require stringent storage conditions such as 
refrigeration. Therefore, the translation of this result into 
clinical practice, given the resource limitations of the 
Kenyan health system and other similar settings, is 
realistic. Because surgical cryotherapy is not routinely 
available, topical ﬂ uorouracil is therefore an alternative 
strategy to prevent recurrence.
The only other randomised study of treatment for 
OSSN was a placebo-controlled, crossover trial of topical 
mitomycin for 48 patients from Australia.10 However, that 
study has several distinct diﬀ erences to our study, which 
probably limit the relevance to settings such as Kenya. 
First, only partial incisional biopsy samples were taken 
for diagnosis; the tumours were not excised. Given the 
advanced and aggressive disease in Africa, complete 
surgical removal of the lesion is the preferred approach. 
Second, the casemix was diﬀ erent: patients with 
squamous cell carcinoma were excluded from the 
Australia study, the population group was older than ours 
(mean age 67 years), predominantly male (75%), and 
probably not infected with HIV (no data were provided). 
Although the lesions regressed clinically on treatment 
with mitomycin, more than half of patients had persistent 
OSSN on repeat histological assessment of the lesion site 
1 year after treatment.
Overall, the use of topical ﬂ uorouracil was associated 
with transient side-eﬀ ects: watery eye, discomfort when 
taking the drops, and eyelid skin inﬂ ammation. However, 
these were mostly mild and resolved after the completion 
of treatment. A transiently positive dye disappearance 
test indicates temporary reversible obstruction of the 
nasolacrimal duct, a known complication of ﬂ uorouracil 
treatment.18 The most signiﬁ cant adverse eﬀ ect was the 
eyelid skin inﬂ ammation. This was reliably prevented by 
protecting the skin with a tissue while applying the drops 
to catch any overﬂ ow. Epiphora was reported by 10% of 
participants at 1 month in the placebo group and 61% 
reported occasional discomfort at 1 month. We think that 
these eﬀ ects were not caused by the placebo, which was a 
bland lubricant, but rather related to having recently had, 
often extensive, excision surgery to remove a tumour. It 
is quite common for excision of conjunctival lesions, 
OSSN or other pathology such as a pterygium, to result 
in a degree of ocular surface inﬂ ammation and irritation 
that can persist for several weeks. Such eﬀ ects are 
especially common in young people of African origin, 
who are more likely to scar and have inﬂ ammation than 
are older white patients.25 Overall, we think that these 
side-eﬀ ects can be partly mitigated, do not usually 
represent a problem after cessation of treatment, and are 
outweighed by the beneﬁ t of the reduced tumour 
recurrence.
Adjunctive ﬂ uorouracil probably works through its 
eﬀ ect on residual OSSN cells that are left after surgical 
excision. It interferes with DNA and RNA processes 
through several active metabolites.26 Fluorodeoxyuridine 
monophosphate inhibits thymidylate synthase, blocking 
thymidylate production, and thus DNA replication. 
Rapidly dividing neoplastic cells are much more 
vulnerable to thymidine depletion than are normal cells. 
Fluorodeoxyuridine triphosphate is misincorporated into 
DNA and ﬂ uorouridine triphosphate is misincorporated 
into RNA. These diﬀ erent metabolites disrupt crucial 
cellular mechanisms, triggering apoptosis.
We were able to follow up participants to 1 year. This 
was attributable to two factors. First, we excluded people 
who said that they would be unlikely to return for follow-
up. Second, the study team were careful to build and 
maintain good relationships with study participants, and 
actively communicated with those who missed follow-
up visits.
Our study has several limitations. First, recruitment 
was slower than anticipated, resulting in a smaller study 
than originally anticipated. The initial study size was 
based on previously reported recurrence rates from 
several case series, with heterogeneous inclusion criteria, 
treatment regimens, and follow-up.4,7,19,22,23,27,28 However, 
the higher than expected recurrence rate and high 
retention enabled us to have good power with a smaller 
sample size. In common with other studies from Africa, 
the recurrence rate in both groups was higher than that 
reported in many case series from temperate countries. 
This diﬀ erence is possibly because OSSN in this 
population, with a high proportion of patients who are 
HIV positive, is more aggressive and patients probably 
present later with more advanced disease.
Second, not all the cases of clinical recurrence had re-
excision and histopathological tests done. However, all 
suspected recurrences for which histopathological 
results were available were conﬁ rmed as recurrent 
OSSN, which suggests that our clinical judgment in this 
situation is highly concordant with the pathology.
Third, we excluded a high proportion of potential 
participants. The most common reason for exclusion was 
that the patient was unlikely to return for follow-up. 
Excluding those who did not think they could return 
helped us achieve good follow-up among those who were 
enrolled in the trial. However, there was no systematic 
diﬀ erence between participants and excluded patients in 
terms of age, sex, HIV status, smoking status, or OSSN 
grade (when those with large lesions requiring alternative 
radical surgery were excluded). This ﬁ nding suggests 
that our results can be generalised. The participants who 
were lost to follow-up attended at least the ﬁ rst visit after 
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randomisation and were recurrence-free at that point. 
The challenge of ensuring high follow-up rates in 
Kenyans with HIV has been reported previously.29
Fourth, we excluded individuals with very large 
tumours that required either enucleation or exenteration. 
This exclusion could reduce the generalisability of the 
ﬁ ndings. However, such patients are not suitable for less 
radical surgery and topical chemotherapy, as the tumour 
is already invading the deeper tissues of the orbit. Finally, 
there were some diﬀ erences in adverse events by group, 
which could have led to unmasking. However, we think 
that this is unlikely: discomfort was common and similar 
in each group at 1 month, and eyelid inﬂ ammation, 
positive dye disappearance test, and epiphora after 
1 month were uncommon.
In conclusion, 4 weeks of topical ﬂ uorouracil 1% after 
surgical excision of OSSN substantially reduced the 
1 year recurrence of tumours. The treatment is safe, 
generally well tolerated, and easy to use. Fluorouracil is 
widely available, aﬀ ordable, and easy to formulate into 
eye drops. It is suitable in settings without cryotherapy. 
Fluorouracil eye drops are an eﬀ ective and realistic 
intervention to improve outcomes for people with OSSN.
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